Alessia Covre Selected Research

dehydroacetic acid (DHAS)

12/2019	Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial.
1/2018	Immunomodulatory Properties of DNA Hypomethylating Agents: Selecting the Optimal Epigenetic Partner for Cancer Immunotherapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alessia Covre Research Topics

Disease

22	Neoplasms (Cancer) 01/2022 - 03/2007
13	Melanoma (Melanoma, Malignant) 01/2022 - 05/2008
7	Testicular Neoplasms (Testicular Cancer) 12/2021 - 05/2008
6	Mesothelioma 12/2021 - 03/2013
3	COVID-19 10/2021 - 01/2020
3	Brain Neoplasms (Brain Tumor) 01/2021 - 01/2017
2	Disease Progression 01/2021 - 04/2010
2	Malignant Mesothelioma 10/2019 - 01/2018
1	Pneumonia (Pneumonitis) 10/2021
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 07/2021
1	Glioblastoma (Glioblastoma Multiforme) 07/2021
1	Lung Neoplasms (Lung Cancer) 01/2020
1	Brain Diseases (Brain Disorder) 10/2019
1	Neoplasm Metastasis (Metastasis) 01/2017
1	Sarcoma (Soft Tissue Sarcoma) 03/2013
1	Renal Cell Carcinoma (Grawitz Tumor) 03/2013
1	Neoplastic Cell Transformation 08/2007
1	Carcinogenesis 08/2007

Drug/Important Bio-Agent (IBA)

8	AntigensIBA 12/2021 - 05/2008
5	DNA (Deoxyribonucleic Acid)IBA 12/2019 - 08/2007
4	guadecitabineIBA 12/2021 - 03/2013
4	Monoclonal AntibodiesIBA 10/2019 - 04/2010
3	MicroRNAs (MicroRNA)IBA 01/2022 - 06/2010
3	durvalumabIBA 01/2021 - 01/2018
3	tremelimumabIBA 01/2021 - 01/2018
3	Messenger RNA (mRNA)IBA 01/2018 - 03/2013
2	IpilimumabIBA 01/2021 - 12/2019
2	Proteins (Proteins, Gene)FDA Link 02/2020 - 03/2013
2	Biomarkers (Surrogate Marker)IBA 02/2020 - 01/2019
2	dehydroacetic acid (DHAS)IBA 12/2019 - 01/2018
2	Decitabine FDA Link 01/2018 - 03/2007
2	AntibodiesIBA 10/2011 - 04/2010
1	Circular RNAIBA 01/2022
1	tazemetostatIBA 12/2021
1	Pharmaceutical PreparationsIBA 10/2021
1	NivolumabIBA 01/2021
1	fotemustine (Muphoran)IBA 01/2021
1	Apoptosis Regulatory ProteinsIBA 02/2020
1	B7-H1 AntigenIBA 02/2020
1	Immune Checkpoint InhibitorsIBA 01/2020
1	Mitogen-Activated Protein KinasesIBA 01/2020
1	RNA (Ribonucleic Acid)IBA 10/2019
1	Cell-Free Nucleic AcidsIBA 01/2019
1	Immune Checkpoint ProteinsIBA 01/2019
1	CytokinesIBA 01/2018
1	Azacitidine (5 Azacytidine)FDA Link 01/2018
1	InterferonsIBA 01/2018
1	Biological ProductsIBA 01/2017
1	Nucleosomes (Nucleosome)IBA 10/2013
1	Histocompatibility Antigens Class IIBA 03/2013
1	antineoplaston A10 (A 10)IBA 03/2013
1	Cytidine DeaminaseIBA 03/2013
1	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 03/2013
1	ElementsIBA 05/2011
1	NucleotidesIBA 05/2011
1	Histones (Histone)IBA 06/2010
1	EndoglinIBA 04/2010

Therapy/Procedure

16	Immunotherapy 12/2021 - 03/2007
11	Therapeutics 01/2022 - 06/2010
1	Biological Therapy 07/2021
1	Retreatment 01/2021
1	Drug Therapy (Chemotherapy) 01/2018